Keynote Speakers Include:
Generating CD8-Selective T Cell Engager Molecules
Mark Cobbold, PhD, Vice President, Oncology Early Discovery, AstraZeneca Pharmaceuticals
Overcoming Tumor Heterogeneity by ex vivo Arming of T Cells Using Multiple Bispecific Antibodies
Nai-Kong V. Cheung, MD, PhD, Enid A. Haupt Endowed Chair, Pediatric Oncology, Memorial Sloan Kettering Cancer Center